Renal adverse effects of nonsteroidal anti-inflammatory drugs

Expert Opinion on Drug Safety

Volumn 8, Issue 6, 2009, Pages 669-681

  Harirforoosh, Sam ^b   Jamali, Fakhreddin ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b EAST TENNESSEE STATE UNIVERSITY   (United States)

Author keywords

Cardiovascular; COX; Kidney; NSAID; Renal failure; Renal side effects

Indexed keywords

4 AMINOPHENAZONE; ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIFLUNISAL; ETODOLAC; ETORICOXIB; FENOPROFEN; IBUPROFEN; INDOMETACIN; KETOROLAC; LUMIRACOXIB; MECLOFENAMIC ACID; MEFENAMIC ACID; MELOXICAM; NAPROXEN; NIFLUMIC ACID; NIMESULIDE; NITRONAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROSTAGLANDIN; ROFECOXIB; SALICYLATE SODIUM; TOLMETIN; UNINDEXED DRUG; VALDECOXIB; ZOMEPIRAC;

ACUTE KIDNEY FAILURE; ARTHRITIS; CARDIOTOXICITY; CARDIOVASCULAR EFFECT; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COLON STRICTURE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; DUODENUM ULCER; EDEMA; ELECTROLYTE EXCRETION; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; GASTROINTESTINAL TRACT; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERKALEMIA; INCIDENCE; INFLAMMATION; INTERSTITIAL NEPHRITIS; KIDNEY; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY PAPILLA NECROSIS; LOW DRUG DOSE; NEPHRITIS; NEPHROTIC SYNDROME; NEPHROTOXICITY; NONHUMAN; OSTEOARTHRITIS; OSTEOPOROSIS; POTASSIUM EXCRETION; PROSTAGLANDIN SYNTHESIS; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SIDE EFFECT; SODIUM EXCRETION; SODIUM RETENTION; STOMACH DISCOMFORT; STOMACH ULCER; TUBULAR DYSFUNCTION; UREA NITROGEN BLOOD LEVEL;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; KIDNEY DISEASES;

EID: 70449480937     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330903311023     Document Type: Review

References (128)

1. Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999;96:7563-7568
2. Bleumink GS, Feenstra J, Sturkenboom MC, Stricker BH. Nonsteroidal anti-inflammatory drugs and heart failure. Drugs 2003;63:525-534
3. Wagner W, Khanna P, Furst DE. Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, nonopioid analgesics, & drugs used in gout. In: Katzung BG, editor, Basic & clinical pharmacology. 9th edition. McGraw-Hill; 2003
4. Laine L. Gastrointestinal effects of NSAIDs and coxibs. J Pain Symptom Manage 2003;25:S32-40
5. Aalykke C, Lauritsen K. Epidemiology of NSAID-related gastroduodenal mucosal injury. Best Pract Res Clin Gastroenterol 2001;15:705-722
6. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998;105:31S-8S
7. Bidaut-Russell M, Gabriel SE. Adverse gastrointestinal effects of NSAIDs: consequences and costs. Best Pract Res Clin Gastroenterol 2001;15:739-753
8. Davies NM, Jamali F. COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. J Pharm Pharm Sci 2004;7:332-336
9. Martel-Pelletier J, Pelletier JP, Fahmi H. Cyclooxygenase-2 and prostaglandins in articular tissues. Semin Arthritis Rheum 2003;33:155-167
10. Barkin RL, Buvanendran A. Focus on the COX-1 and COX-2 agents: renal events of nonsteroidal and anti-inflammatory drugs-NSAIDs. Am J Ther 2004;11:124-129
11. Fitzgerald GA. Prostaglandins, aspirin, and related compounds. In: GoldmanL, AusielloD, editors, Cecil textbook of medicine. 22nd edition. Elsevier Science Health Science div; 2003
12. Celotti F, Laufer S. Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept. Pharmacol Res 2001;43:429-436
13. Smyth EM, Fitzgerald GA. Human prostacyclin receptor. Vitam Horm 2002;65:149-165
14. Wu KK, Liou JY, Cieslik K. Control of COX-2 Transcriptional activation by proinflammatory mediators. Arterioscler Thromb Vasc Biol 2005;25:679-685
15. Agnoli GC, Borgatti R, Cacciari M, et al. Renal synthesis of prostacyclin and thromboxane in healthy women: differential effects of a short-term saline loading. Prostaglandins Leukot Essent Fatty Acids 2000;62:111-117
16. Nielsen CB, Bech JN, Pedersen EB. Effects of prostacyclin on renal haemodynamics, renal tubular function and vasoactive hormones in healthy humans. A placebo-controlled dose-response study. Br J Clin Pharmacol 1997;44:471-476
17. Bonvalet JP, Pradelles P, Farman N. Segmental synthesis and actions of prostaglandins along the nephron. Am J Physiol 1987;253:F377-87
18. Villa E, Garcia-Robles R, Haas J, Romero JC. Comparative effect of PGE2 and PGI2 on renal function. Hypertension 1997;30:664-666
19. Wagner C, Jensen BL, Kramer BK, Kurtz A. Control of the renal renin system by local factors. Kidney Int Suppl 1998;67:S78-83
20. Shibata M, Kodani I, Osaki M, et al. Cyclo-oxygenase-1 and -2 expression in human oral mucosa, dysplasias and squamous cell carcinomas and their pathological significance. Oral Oncol 2005;41:304-312
21. Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol Suppl 1997;49:15-19
22. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120
23. Hoffmann C. COX-2 in brain and spinal cord implications for therapeutic use. Curr Med Chem 2000;7:1113-1120
24. Porcher C, Horowitz B, Bayguinov O, et al. Constitutive expression and function of cyclooxygenase-2 in murine gastric muscles. Gastroenterology 2002;122:1442-1454
25. Porcher C, Horowitz B, Ward SM, Sanders KM. Constitutive and functional expression of cyclooxygenase 2 in the murine proximal colon. Neurogastroenterol Motil 2004;16:785-799
26. Adegboyega PA, Ololade O. Immunohistochemical expression of cyclooxygenase-2 in normal kidneys. Appl Immunohistochem Mol Morphol 2004;12:71-74
27. Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 2002;99:13926-13931
28. Martel-Pelletier J, Pelletier JP, Fahmi H. New insights into prostaglandin biology. J Rheumatol 2004;31:14-16
29. Dinchuk JE, Liu RQ, Trzaskos JM. COX-3: in the wrong frame in mind. Immunol Lett 2003;86:121
30. Harris RC, McKanna JA, Akai Y, et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994;94:2504-2510
31. Khan KN, Venturini CM, Bunch RT, et al. Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal antiinflammatory drug-related nephrotoxicity. Toxicol Pathol 1998;26:612-620
32. Athirakul K, Kim HS, Audoly LP, et al. Deficiency of COX-1 causes natriuresis and enhanced sensitivity to ACE inhibition. Kidney Int 2001;60:2324-2329
33. Ye W, Zhang H, Hillas E, et al. Expression and function of COX isoforms in renal medulla: evidence for regulation of salt sensitivity and blood pressure. Am J Physiol Renal Physiol 2006;290:F542-9
34. Dinchuk JE, Car BD, Focht RJ, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995;378:406-409
35. Martin SP, Hortelano S, Bosca L, Casado M. Cyclooxygenase 2: understanding the pathophysiological role through genetically altered mouse models. Front Biosci 2006;11:2876-2888
36. Kim SM, Chen L, Mizel D, et al. Low plasma renin and reduced renin secretory responses to acute stimuli in conscious COX-2-deficient mice. Am J Physiol Renal Physiol 2007;292:F415-22
37. Yang T, Endo Y, Huang YG, et al. Renin expression in COX-2-knockout mice on normal or low-salt diets. Am J Physiol Renal Physiol 2000;279:F819-25
38. Patel NS, Cuzzocrea S, Collino M, et al. The role of cycloxygenase-2 in the rodent kidney following ischaemia/reperfusion injury in vivo. Eur J Pharmacol 2007;562:148-154
39. Hawkey CJ. COX-2 inhibitors. Lancet 1999;353:307-314
40. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004;18:790-804
41. AHFS Drug Information. American Society of Health-System Pharmacists; 2008
42. De Mello NR, Baracat EC, Tomaz G, et al. Double-blind study to evaluate efficacy and safety of meloxicam 7.5 mg and 15 mg versus mefenamic acid 1500 mg in the treatment of primary dysmenorrhea. Acta Obstet Gynecol Scand 2004;83:667-673
43. Calvo AM, Sakai VT, Giglio FP, et al. Analgesic and anti-inflammatory dose-response relationship of 7.5 and 15 mg meloxicam after lower third molar removal: a double-blind, randomized, crossover study. Int J Oral Maxillofac Surg 2007;36:26-31
44. Jordan S, White J. Non-steroidal anti-inflammatory drugs: clinical issues. Nurs Stand 2001;15:45-52
45. Verbeeck RK, Blackburn JL, Loewen GR. Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs. Clin Pharmacokinet 1983;8:297-331
46. Maiden L, Thjodleifsson B, Seigal A, et al. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol 2007;5:1040-1045
47. Fu JY, Masferrer JL, Seibert K, et al. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990;265:16737-16740
48. Becker JC, Domschke W, Pohle T. Current approaches to prevent NSAID-induced gastropathy-COX selectivity and beyond. Br J Clin Pharmacol 2004;58:587-600
49. Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol 1991;31:588-598
50. Breyer MD, Harris RC. Cyclooxygenase 2 and the kidney. Curr Opin Nephrol Hypertens 2001;10:89-98
51. Bush TM, Shlotzhauer TL, Imai K. Nonsteroidal anti-inflammatory drugs. Proposed guidelines for monitoring toxicity. West J Med 1991;155:39-42
52. Segal R, Lubart E, Leibovitz A, et al. Renal effects of low dose aspirin in elderly patients. Isr Med Assoc J 2006;8:679-682
53. Whelton A, Maurath CJ, Verburg KM, Geis GS. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther 2000;7:159-175
54. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortalityand cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med 2009;169:141-149
55. Huledal G, Jonzon B, Malmenas M, et al. Renal effects of the cyclooxygenase-inhibiting nitric oxide donator AZD3582 compared with rofecoxib and naproxen during normal and low sodium intake. Clin Pharmacol Ther 2005;77:437-450
56. Karlsson J, Pivodic A, Aguirre D, Schnitzer TJ. Efficacy, safety, and tolerability of the cyclooxygenase-inhibiting nitric oxide donator naproxcinod in treating osteoarthritis of the hip or knee. J Rheumatol 2009;36:1290-1297
57. Whelton A, Stout RL, Spilman PS, Klassen DK. Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure. A prospective, randomized, crossover comparison. Ann Intern Med 1990;112:568-576
58. Ulinski T, Guigonis V, Dunan O, Bensman A. Acute renal failure after treatment with non-steroidal anti-inflammatory drugs. Eur J Pediatr 2004;163:148-150
59. Gambaro G, Perazella MA. Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. J Intern Med 2003;253:643-652
60. Brater DC. Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition. Am J Med 1999;107:65S-70S
61. Buck ML, Norwood VF. Ketorolac-induced acute renal failure in a previously healthy adolescent. Pediatrics 1996;98:294-296
62. Chan XM. Fatal renal failure due to indomethacin. Lancet 1987;2:340
63. Ezra E, Caspi I, Weiss J, et al. Acute reversible renal failure following naproxen (naxyn) administration. Scand J Rheumatol 1986;15:401-402
64. Spierto RJ, Kaufman MB, Stoukides CA. Acute renal failure associated with the use of over-the-counter ibuprofen. Ann Pharmacother 1992;26:714
65. Graham MG. Acute renal failure related to high-dose celecoxib. Ann Intern Med 2001;135:69-70
66. Wolf G, Porth J, Stahl RA. Acute renal failure associated with rofecoxib. Ann Intern Med 2000;133:394
67. Szalat A, Krasilnikov I, Bloch A, et al. Acute renal failure and interstitial nephritis in a patient treated with rofecoxib: case report and review of the literature. Arthritis Rheum 2004;51:670-673
68. Morales E, Mucksavage JJ. Cyclooxygenase-2 inhibitor-associated acute renal failure: case report with rofecoxib and review of the literature. Pharmacotherapy 2002;22:1317-1321
69. Mühlfeld AS, Floege J. COX-2 inhibitor induced anuric renal failure in a previously healthy young woman. Clin Nephrol 2005;63:221-224
70. Rossi E, Ferraccioli GF, Cavalieri F, et al. Diclofenac-associated acute renal failure. Report of 2 cases. Nephron 1985;40:491-493
71. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999;106:13S-24S
72. Patel H, Barr A, Jeejeebhoy KN. Renal effects of long-term treatment with 5-aminosalicylic acid. Can J Gastroenterol 2009;23:170-176
73. Sugimoto T, Yasuda M, Sakaguchi M, et al. Acute interstitial nephritis associated with etanercept. Rheumatol Int 2008;28:1283-1284
74. Wiseman EH, Reinert H. Anti-inflammatory drugs and renal papillary necrosis. Agents Actions 1975;5:322-325
75. Kovacevic L, Bernstein J, Valentini RP, et al. Renal papillary necrosis induced by naproxen. Pediatr Nephrol 2003;18:826-829
76. Atta MG, Whelton A. Acute renal papillary necrosis induced by ibuprofen. Am J Ther 1997;4:55-60
77. Gradus DB, Zuker N, Barki Y. Renal papillary necrosis in a child with rheumatic carditis treated with aspirin. Isr J Med Sci 1989;25:196-198
78. Colome NE, Solans R, Espinach J, et al. Renal papillary necrosis induced by flurbiprofen. DICP 1991;25:870-871
79. Mitchell H, Muirden KD, Kincaid-Smith P. Indamethacin-induced renal papillary necrosis in juvenile chronic arthritis. Lancet 1982;2:558-559
80. Akhund L, Quinet RJ, Ishaq S. Celecoxib-related renal papillary necrosis. Arch Intern Med 2003;163:114-115
81. Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. Am J Med 2000;109:307-314
82. Stichtenoth DO, Frolich JC. COX-2 and the kidneys. Curr Pharm Des 2000;6:1737-1753
83. Alva JP, Kotian G. Diclofenac induced renal dysfunction presenting as cardiac arrhythmia. J Assoc Physicians India 2001;49:749-752
84. Ray PE, Rigolizzo D, Wara DR, Piel CF. Naproxen nephrotoxicity in a 2-year-old child. Am J Dis Child 1988;142:524-525
85. Marasco WA, Gikas PW, Azziz-Baumgartner R, et al. Ibuprofen-associated renal dysfunction. Pathophysiologic mechanisms of acute renal failure, hyperkalemia, tubular necrosis, and proteinuria. Arch Intern Med 1987;147:2107-2116
86. Miller KP, Lazar EJ, Fotino S. Severe hyperkalemia during piroxicam therapy. Arch Intern Med 1984;144:2414-2415
87. Palmer BF. Renal complications associated with use of nonsteroidal anti-inflammatory agents. J Investig Med 1995;43:516-533
88. Schwartz JI, Vandormael K, Malice MP, et al. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther 2002;72:50-61
89. Kaji DM, Chase HS Jr, Eng JP, Diaz J. Prostaglandin E2 inhibits Na-K-2Cl cotransport in medullary thick ascending limb cells. Am J Physiol 1996;271:C354-61 (Pubitemid 26298811)
90. Fernandez-Llama P, Ecelbarger CA, Ware JA, et al. Cyclooxygenase inhibitors increase Na-K-2Cl cotransporter abundance in thick ascending limb of Henle's loop. Am J Physiol 1999;277:F219-26
91. Cowley AW Jr, Mattson DL, Lu S, Roman RJ. The renal medulla and hypertension. Hypertension 1995;25:663-673
92. Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999;289:735-741
93. Komers R, Anderson S, Epstein M. Renal and cardiovascular effects of selectivecyclooxygenase-2 inhibitors. Am J Kidney Dis 2001;38:1145-1157
94. Swan SK, Rudy DW, Lasseter KC, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med 2000;133:1-9
95. Rossat J, Maillard M, Nussberger J, et al. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999;66:76-84
96. Warner TD, Mitchell JA. COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Lancet 2008;371:270-273
97. Cheng HF, Harris RC. Cyclooxygenases, the kidney, and hypertension. Hypertension 2004;43:525-530
98. Alderman M, Sealey J, Cohen H, et al. Urinary sodium excretion and myocardial infarction in hypertensive patients: a prospective cohort study. Am J Clin Nutr 1997;65:682S-6S
99. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-1102
100. Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005;142:481-489
101. Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004;364:675-684
102. Juhlin T, Jönsson BA, Höglund P. Renal effects of aspirin are clearly dose-dependent and are of clinical importance from a dose of 160 mg. Eur J Heart Fail 2008;10:892-898
103. Gooch K, Culleton BF, Manns BJ, et al. NSAID use and progression of chronic kidney disease. Am J Med 2007;120:280-287
104. Harirforoosh S, Jamali F. Effect of nonsteroidal anti-inflammatory drugs with varying extent of COX-2/COX-1 selectivity on urinary sodium and potassium excretion in the rat. Can J Physiol Pharmacol 2005;83:85-90
105. Harirforoosh S, Aghazadeh-Habashi A, Jamali F. Extent of renal effect of cyclo-oxygenase-2-selective inhibitors is pharmacokinetic dependent. Clin Exp Pharmacol Physiol 2006;33:917-924
106. Goodman LA, Brown SA, Torres BT, et al. Effects of meloxicam on plasma iohexol clearance as a marker of glomerular filtration rate in conscious healthy cats. Am J Vet Res 2009;70:826-830
107. Gunew MN, Menrath VH, Marshall RD. Long-term safety, efficacy and palatability of oral meloxicam at 0.01-0.03 mg/kg for treatment of osteoarthritic pain in cats. J Feline Med Surg 2008;10:235-241
108. Junot S, Troncy E, Keroack S, et al. Renal effect of meloxicam versus ketoprofen in anaesthetized pseudo-normovolaemic piglets. Can J Physiol Pharmacol 2008;86:55-63
109. Fusellier M, Desfontis JC, Le RA, et al. Effect of short-term treatment with meloxicam and pimobendan on the renal function in healthy beagle dogs. J Vet Pharmacol Ther 2008;31:150-155
110. Zeidler H, Kaltwasser JP, Leonard JP, et al. Prescription and tolerability of meloxicam in day-to-day practice: postmarketing observational cohort study of 13,307 patients in Germany. J Clin Rheumatol 2002;8:305-315
111. Henry D, Page J, Whyte I, et al. Consumption of non-steroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects. Results of a case-control study. Br J Clin Pharmacol 1997;44:85-90
112. Caspi D, Lubart E, Graff E, et al. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum 2000;43:103-108
113. Fries S, Grosser T, Price TS, et al. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology 2006;130:55-64
114. Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005;77:1-16
115. Jamali F. Arthritis is associated with cardiovascular disease in the users of analgesics and nonsteroidal anti-inflammatory drugs. Arch Intern Med 2007;167:2371-2372
116. Niederstadt C, Happ T, Tatsis E, et al. Glomerular and tubular proteinuria as markers of nephropathy in rheumatoid arthritis. Rheumatology (Oxford) 1999;38:28-33
117. Cherney DZ, Miller JA, Scholey JW, et al. The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes. Diabetes 2008;57:688-695
118. Baker J, Cotter JD, Gerrard DF, et al. Effects of indomethacin and celecoxib on renal function in athletes. Med Sci Sports Exerc 2005;37:712-717
119. Akima S, Kent A, Reynolds GJ, et al. Indomethacin and renal impairment in neonates. Pediatr Nephrol 2004;19:490-493
120. Srinivasjois RM, Nathan EA, Doherty DA, Patole SK. Renal impairment associated with indomethacin treatment for patent ductus arteriosus in extremely preterm neonates-is postnatal age at start of treatment important? J Matern Fetal Neonatal Med 2006;19:793-799
121. Schlondorff D. Renal prostaglandin synthesis. Sites of production and specific actions of prostaglandins. Am J Med 1986;81:1-11
122. Davies NM, Longstreth J, Jamali F. Misoprostol therapeutics revisited. Pharmacotherapy 2001;21:60-73
123. Munger MA, Gardner SF, Ateshkadi A, et al. Misoprostol effects on diclofenac-induced cardiorenal changes in salt-sensitive patients with hypertension: the MEDIC Study. Pharmacotherapy 2008;28:834-842
124. Weir MR, Klassen DK, Hall PS, et al. Minimization of indomethacin-induced reduction in renal function by misoprostol. J Clin Pharmacol 1991;31:729-735
125. Boers M, Dijkmans BA, Breedveld FC, et al. No effect of misoprostol on renal function of rheumatoid patients treated with diclofenac. Br J Rheumatol 1991;30:56-59
126. Pamuk ON, Cakir N. The renal effects of the addition of low-dose aspirin to COX-2 selective and nonselective antiinflammatory drugs. Clin Rheumatol 2006;25:123-5
127. Juhlin T, Bjorkman S, Gunnarsson B, et al. Acute administration of diclofenac, but possibly not long term low dose aspirin, causes detrimental renal effects in heart failure patients treated with ACE-inhibitors. Eur J Heart Fail 2004;6:909-916
128. Schutt B, Kunz M, Blode H. Coadministration of estradiol/ drospirenone and indomethacin does not cause hyperkalemia in healthy postmenopausal women: a randomized open-label crossover study. J Clin Pharmacol 2007;47:774-781